Largactil Iv (Chlorpromazine Hydrochloride)

Chlorpromazine blocks dopamine D2 receptors and also antagonises serotonin, histamine, and adrenergic receptors. This multi‑receptor blockade reduces psychotic symptoms, provides anti‑emetic action, and produces sedation, addressing the diverse clinical uses of the drug.

The specific dose of Largactil Iv is determined by the prescribing clinician based on the patient’s condition, severity, age, weight, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal therapeutic outcomes while minimizing adverse effects.

Chlorpromazine is classified as Pregnancy Category B, indicating no evidence of fetal risk in animal studies, but adequate human data are lacking. Use during pregnancy or lactation should only occur when the potential benefit justifies any potential risk, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and necessary import documentation.

Largactil Iv (chlorpromazine) is a first‑generation, phenothiazine antipsychotic, whereas many newer agents belong to the second‑generation (atypical) class. Chlorpromazine has a broader receptor profile, leading to more pronounced anticholinergic and sedative effects, while atypicals often have lower risk of extrapyramidal symptoms but may carry metabolic side‑effects.

Largactil Iv should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use to maintain stability and sterility.

Largactil Iv is given by slow intravenous injection or infusion under medical supervision. The rate of administration is adjusted according to the clinical indication and patient tolerance, and vital signs are monitored throughout the procedure.

Serious risks include neuroleptic malignant syndrome, agranulocytosis, severe hypotension, cardiac arrhythmias such as QT prolongation, and tardive dyskinesia. Prompt recognition and immediate medical intervention are essential if any of these events occur.

Largactil Iv is contraindicated in patients with known hypersensitivity to chlorpromazine or any phenothiazine component, in those with severe cardiovascular disease that could be worsened by hypotension, and in individuals with a history of neuroleptic malignant syndrome. Caution is also advised for patients with significant hepatic impairment.